Scholars LITERATURE

International Journal of Integrative Cardiology

Review Article

DOI: https://doi.org/10.47275/2690-862X-128
Volume 4 Issue 1

Efficacy of NOACs in Valvular and Non-Valvular Atrial Fibrillation: A Systematic Review

Sri Ram Charan G[1]*, Sai Sandeep D[2], Namratha Vaghdevi Cherukuru[3], Prashasti Sharma[3] and Sahithi G[3]

[1]Rangaraya Medical College and Hospital, Kakinada, India

[2]Kurnool Medical College and Hospital, Kisan Ghat Road, Kurnool, India

[3]Sri Padmavathi Medical college for Women, SVIMS University, Tirupathi, India

Abstract

Background and objective: Evaluation of NOACs efficacy, including apixaban, edoxaban, dabigatran, and rivaroxaban, as compared to warfarin in patient role with non valvular AF, including patients at severe risk of bleeding and who received treatment with low doses of NOAC, in terms of safety, such as bleeding risk, and effectiveness, such as the stroke risk or systemic intercalation.

Methods: To find the relevant data on the effects of NOACs in valvular and nonvalvular, a thorough search strategy was performed to search through electronic databases such as PubMed, Cochrane, Google Scholar, Science Direct, and EMBASE. A cumulative of 1728 research papers were retrieved in the search results, which were then examined using the PRISMA principles and the eligibility criteria to find only the most valuable and appropriate research.

Results: Dabigatran, edoxaban, rivaroxaban, and apixaban (NOACs), have revolutionized the treatment of AF though regulatory authorities only permit them for stroke prophylaxis in affected roles with non valvular AF. This terminology has laid confusion around which patient role with the valvular heart-related disease gets an advantage from the NOACs and which ought to be treated with vitamin K antagonist. The essential trials showing the superiority of NOACs to VKAs included individuals with VHD other than MPV and severe mitral stenosis, and consensus recommendations advise NOACs more than VKAs in those individuals. They have dedicated succeeding patient-centered randomized controlled studies. Transcatheter and bioprosthetic valves for those with AF have both attested to the safety and usefulness of NOACs in these people. Observational research papers suggest that NOACs could be safer and more useful in people with rheumatic mitral stenosis.

Conclusions: NOACs lowered the chances of venous thromboembolism, cerebral bleeding, and death while having an equal chance of ischemic stroke and hemorrhaging in patient role with AF and Valvular heart diseases. As a result, NOAC is a powerful and secure substitute for warfarin in these people.

Keywords: Valvular Heart Disease; Atrial Fibrillation; Warfarin; Dabigatran; Edoxaban; Rivaroxaban; Apixaban; Non-Vitamin K Antagonist Oral Anticoagulants (NOACs)

Correspondence to: Dudekonda Sai Sandeep, Kurnool Medical College, Kurnool, Andhra Pradesh, India; E-mail: saisandeep330@gmail.com

Citation: Sri Ram Charan G, Sai Sandeep D, Cherukuru NV, Sharma P, Gunduru S (2022) Efficacy of NOACs in Valvular and Non-Valvular Atrial Fibrillation: A Systematic Review. Int J Integr Cardiol, Volume 4:1. 128. DOI: https://doi.org/10.47275/2690-862X-128

Received: September 15, 2022; **Accepted:** October 07, 2022; **Published:** October 12, 2022

Abbreviations

AF: Atrial fibrillation

ARISTOTLE: Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation

LPB: Largest population-based

MB: Major bleeding

MPV: Mechanical prosthetic valves

NOACs: Non-vitamin K antagonist oral anticoagulants

NVAF: Nonvalvular atrial fibrillation

VHD: Valvular heart disease

VKAs: Vitamin K antagonists

Introduction

Globally, atrial fibrillation (AF) prevalence is about 37000 million, which has been a major cause of related mortalities. In Japan, the incidences of AF are less than 1% of the country's population as one of the most prevalent arrhythmia [1]. For over the past five decades, warfarin has been the prioritized drug employed to treat strokes associated with AF. Today, the advancement in the field of medicine has led to the emergence of a new kind of anticoagulant drug with more efficacy and options. Although, the prevalence of AF increases with age to an extent where individuals nearing 80 years of age are at high risk of developing AF, reaching about 14% [1,2]. Stroke, systemic embolism, and mortality are all at risk because of AF [3,4]. For eligible individuals with non-valvular atrial fibrillation who have never used an oral anticoagulant, recent guidelines advise treating them with NOACs (apixaban, edoxaban, dabigatran, and rivaroxaban) [2,5]. Numerous randomized controlled studies have substantiated the advantages

of NOACs over warfarin in people with NVAF, and a meta-analysis has confirmed that NOACs considerably reduce the stroke risk or SE with a risk of great bleeding that is comparable to that of warfarin [6-10]. Although RCTs are the best standard for proving the efficacy of therapies, their partial representation of a randomly chosen world population limits the applicability of their outcomes to clinical practice [11-14]. As a result, various observational, World evidence studies have been conducted to prove that NOACs are safe and efficacious for use in therapeutic settings [15-18].

However, there are still a number of unresolved knowledge breaches in the literature addressing the clinical results of treatment with NOAC inpatient roles with NVAF, especially inpatient subcategories with a high chance of unfavorable outcomes [19,20]. To treat affected roles with NVAF at risk for stroke and SE, Japan has approved all NOACs (apixaban, edoxaban, dabigatran, and rivaroxaban) [21]. Certain the greater bleeding problem rates recorded in East Asian individuals, it is significant that the dosage of NOACs like in Japan varies a little from that in other nations; for instance, the permitted dosage of rivaroxaban in Japan is 10 mg to 15 mg every day [21]. Given the special circumstances surrounding their administration and the fact that they are frequently started at lower doses, more research is needed to determine how NOACs affect the safety and efficacy outcomes of patients with NVAF in Japan.

Any kind of AF increases the risk of thromboembolism due to the development of atrial thrombi. Henceforth, long-term oral anticoagulation is advised for the majority of AF patients. Regardless of baseline risk, anticoagulation decreases the thromboembolic risks by roughly 2-3rd [22]. All antithrombotic medications did, however, increase the bleeding risk, with cerebral haemorrhage being the most severe bleeding consequence. Oral anticoagulants that are non-vitamin K antagonists have been added to the treatment arsenal for the subordinate and primary prevention of thromboembolic occurrence in patients with AF. In randomized controlled trials, anticoagulation with slightly of the accepted NOACs associated with comparable or reduced rates of severe bleeding and ischemic stroke in patients with AF and a risk of cerebral haemorrhage that was less than half that of warfarin at the adjusted dose [6,10].

Individuals with mechanical valves, rheumatic heart disease, and mitral stenosis has been excluded from the majority of medical trials of antithrombotic treatment in patients with AF. Independent of the fundamental cardiac rhythm, valvular heart disease is present in more than 50% of individuals with AF and is linked to an increased risk of thromboembolic events [23]. AF predicts a significant thromboembolic risk in individuals with mitral valve stenosis and prosthetic valves, and vitamin K antagonists are recommended for stroke and systemic embolism prevention [24]. The NOAC trials have included several patients with VHD. 26% of participants in the ARISTOTLE trial had a history of severe or moderate VHD, most having mitral vomiting or having undergone earlier valve surgery [25]. There was no evidence that patients with and without VHD experienced different effects of apixaban relative to warfarin on stroke, severe bleeding, or all-cause mortality, despite the fact that these individuals had greater rates of systemic embolism and stroke than those without. 14.1% of people with severe VHD and 5.3% of people with past valvular operations were found in a post hoc examination of the ROCKET-AF ((Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation)) [26]. Systemic thromboembolism and all-cause death rates among patients with VHD were comparable, although the risk of severe bleeding was considerably higher with rivaroxaban than with warfarin. The existence of VHD could not change the comparison among warfarin and dabigatran, according to a recent study of the RE-LY trial ((Randomized Evaluation of Long-Term Anticoagulation Therapy), which also showed that 21.8% of patients with AF had it [27].

Warfarin and other VKAs used to be the typical care for individuals with non-valvular AF who wanted to prevent strokes [28]. Warfarin anticoagulation has been replaced by the non-vitamin K antagonist OACs (oral anticoagulants) apixaban, rivaroxaban, dabigatran, and edoxaban because they are more practical, effective, and acceptable [10]. The NOACs are being utilized more frequently in standard clinical practice, which is not surprising. Due to these variations, it is crucial to assess whether an AF patient role with a history of bleeding can experience different results when treated with NOACs as opposed to warfarin [29,30]. As their use continues to rise, more information will also be required to fully comprehend the risk-benefit profiles linked to individually NOAC. The majority of studies on anticoagulant treatment in AF after a significant hemorrhagic occurrence have, to date, concentrated on warfarin treatment alone or warfarin compared to NOACs together rather than contrasting the various NOACs versus warfarin and to one another [31-33]. Pharmacokinetic variations among NOACs might alter their individual efficiency and safety, and this is a crucial omission. Data on this particular segment of the AF sample could be important for making therapeutic choices, assuming that the efficacy and tolerability of pharmaceutical treatment in people with NVAF can be prejudiced by pre-existing individual comorbidities, such as past bleeding. This research compared the risk of stroke, MB, and SE among NVAF individuals with past bleeding linked with NOACs in valvular and non-valvular AF compared to warfarin and one another.

Materials and Methods

Study Design

All of the primary research papers included in this systematic review were thoroughly searched using the most preferred and recommended reporting tools for systematic Review and Meta-Analysis (PRISMA) methods and requirements [34]. For the most relevant articles related to the study topic, a thorough search of five electronic databases, including EMBASE, PubMed, Cochrane Library, Science Direct, and Google Scholar, was conducted.

Search Strategy

All five databases were searched thoroughly and broadly to identify the most relevant publications for this analysis. For the search processes, the appropriate keyword and Boolean operators like “AND” and “OR” were employed to provide simple search tab navigation through the particular database. (“Efficacy” OR “efficiency” OR “effectiveness” OR “effect” OR “safety”) AND (“NOAC” OR “Apixaban” OR “Dabigatran” OR “Edoxaban” OR “Rivaroxaban”) are some pertinent keywords that were used. This method makes it possible to identify the crucial ideas related to the efficiency of NOACs in both valvular and nonvalvular AF.

Eligibility criteria

Inclusion and exclusion criteria: Utilizing the inclusion and exclusion study appropriateness, the original and most pertinent studies pertaining to the effectiveness of NOAC enhancers in the topical treatment of heart disease and prevention of stroke for patients with nonvalvular AF were discovered and included for analysis. It was

determined that a survey was appropriate for this systemic evaluation based on whether or not a survey matched the following inclusion criteria.

- Research performance between 2015 and 2022
- Research covering the topical therapy of conditions related to the heart.
- Research-based studies on the capacity of NOACs to avert stroke.

However, for the following reasons, articles were disregarded and deemed unsuitable for inclusion in this systematic review.

- Studies relying on secondary data sources, such as reported instances of NOACs' efficacy in other systematic reviews.
- Articles that were undertaken in languages other than English, published before 2015, or conducted in any other language than English.

Data extraction

Two reviewers tasked with studying and rating the research papers pertinent to this systematic review were given the duty of extracting data. Following the PICO (patient, intervention, comparison, and outcomes) recommendations, the two experts independently evaluated the studies, identifying important study elements, including study designs, sample sizes (number of participants), authors, the year of publication, and results.

Results and Analysis

Search Results

The PRISMA rules governing the process of information search for publications published between 2015 and 2022 were fully adhered to in this study's search strategy. By adding important terms such NOACs and valvular or non-valvular, a more thorough search was conducted, requiring the retrieval of 1525 results articles in the initial search of the electronic databases. Topical therapy and stroke prevention were included in the second search, which led to 203 total findings that were published between 2016 and 2020. Following that, other searches were made, such as using the full title to search the databases for pertinent data, as shown in Figure 1 below the PRISMA summary table. The next section discusses the most important references found during the search process.

Study characteristics of the included articles

Regarding the efficacy outcome from the included studies, data were extracted on cases of stroke, ischemic stroke, transient ischemic attack, and thromboembolism. The various measurement units employed in determining the treatment efficacy of NOACs compared to warfarin revealed that patients treated with NOACs had lower incidences of these stroke-associated conditions (Table 2). Individual studies in table 2 above show that the events and incidences of IS, S, HS, and TIA are higher in the group treated with warfarin than in the NOACs group (Table 2).



Figure 1: The PRISMA flow chart outlines the search method and the number of studies that were found.

Table 1: Baseline characteristic of patients' outcomes between NOACs and Comparator.

Study ID	Study design	Participants			Intervention		Period		Comparator		Results
		No.	*Age (yrs.)*	*Gender F/M*	*N*	*NOACs*	*Treatment*	*Follow-up (months)*	*N*	*Control*	
Li HJ, et al. (2021) [35]	Retrospective cohort study	17311	73.75 ± 10.1	7531 (M) 7770 (F)	6566	R, D	Jan 2012-Dec 2015	6.5 for D and 5.7 for R 7.7 for W	8735	W	T, IS, VTE, GI bleeding, ICH
Kohsaka S, et al. (2020) [36]	Retrospective study	73989	76.0±10.3	48894 (M) 25095 (F)	42087	R, D, A, E	725 days	12	15902	W	ICH, GI, SE, IS
Briasoulis A, et al. (2018) [37]	Retrospective cohort study	20525	76±6	-	4302	R, D	Nov 2011 to Oct 2013	12	16223	W	MI, PVD, ICD
Nielsen PB, et al. (2019) [38]	Nationwide observational cohort	622	77.4	243 (F) 379 (M)	348	NOACs	Jan 2003-April 2017	12	274	W	IS, T, MB
Chan YH, et al. (2018) [39]	National retrospective cohort study	73074	75±10	31204(F) 41870(M)	53699	A, R, D	June 2012- Dec 2016	18.6	19375	W	IS, SE, ICH, MB
Melgaard L, et al. (2021) [40]	Observational study	3726	79	1760 (F) 1966 (M)	2357	A, D, E, R	2013-2018	13	1369	W	MB, IS, T
Crocetti E, et al. (2021) [41]	Population-based retrospective study	8543	73	4079(F) 4464(M)	7440	D, R, A, E	Jan 2017-dec 2019	24	1103	W	MI, SE, MB, ICD
Lip GY, et al. (2021) [33]	Retrospective cohort study	381054	75	187489(F) 50.8% (M)	235991	A, D, R	Jan 2012 to Sept 2015	1	145063	W	GI, SE, MB
Fanaroff AC, et al. (2022) [42]	Retrospective study	71531	-	-	57946	D, A, R, E	2011 to 2012	27	13585	VKA	MB, SE, T

R: rivaroxaban; D: dabigatran; T: thromboembolic; GI: gastrointestinal; ICH: intracranial hemorrhage; W: warfarin; A: apixaban;
E: edoxaban; SE: Systemic embolism; PVD: peripheral vascular disease; MI: myocardial infarction; ICD: internal cardioverter defibrillator

Table 2: Efficacy outcomes of various NAOCs against the comparators among the included studies.

Study	NOACs				Comparator
	Dabigatran	*Rivaroxaban*	*Apixaban*	*Edoxaban*	
Crocetti E, et al. (2021) [41]	S - 0.59 (20.1)	S - 0.77 (24.7)	S - 0.74 (2721)	S - 0.72 (25.4)	Warfarin S - 36.6 (27.4-48.8)
Fanaroff AC, et al. (2022) [42]	Tb - 1.94	Tb - 0.65	Tb - 1.02	Tb - 1.02	VKA
Melgaard L, et al. (2021) [40]	Tb - 1.62 (1.08-2.45)	Tb - 1.92 (1.11-3.30	_	_	Warfarin Tb
Chan YH, et al. (2018) [39]	Tb - 2.74* IS - 2.4*	Tb - 2.84* IS - 2.53*	Tb - 2.26* IS - 2.06*	_	Warfarin Tb - 3.26* IS - 2.79*
Lip GY, et al. (2021) [33]	S - 1.53[a] IS - 1.27[a] SE - 0.07[a]	S - 1.61[a] IS - 1.17[a] SE - 0.07[a]	S - 2.16[a] IS - 1.48[a] SE - 0.03[a]	_	Warfarin S - 2.16[a] IS - 1.48[a] SE - 0.09[a]
Nielsen PB, et al. (2019) [38]	IS- 4.01% (2.02% to 6.14%)	IS- 8.83% (5.32% to 11.23%)	_	_	Warfarin IS - 7.85% (4.50% to 11.20%)
Briasoulis A, et al. (2018) [37]	S - 1.4 (129)[b]	S - 1.2 (99)[b]	_	_	Warfarin S - 1.9 (696)[b]
Kohsaka S, et al. (2020) [36]	IS - 0.9 [0.716 to 1.140] HS - 0.41 [0.244 to 0.703] Tb - 0.97 [0.316 to 2.959]	IS - 0.74 [0.607 to 0.91] HS - 0.63 [0.432 to 0.922] Tb - 0.5 [0.183 to 1.349]	IS - 0.63 [0.607 to 0.91] HS - 0.63 [0.432 to 0.922] Tb - 0.5 [0.183 to 1.349]	IS - 0.74 [0.586 to 0.93] HS - 0.73 [0.479 to 1.102] Tb - 0.46 [0.145 to 1.487]	Warfarin
Li HJ, et al. (2021) [35]	IS - 7.07[a] (6.11-8.19) TIA - 1.21[a] (0.86-1.71) Tb - 0.11[a] (0.04-0.35)	IS - 7.16[a] (6.04-8.49) TIA - 1.05[a] (0.86-1.71) Tb - 0.42[a] (0.21-0.84)	_	_	Warfarin IS - 7.04[a] (6.04-7.74) TIA - 0.89[a] (0.69-1.15) Tb - 0.54[a] (0.39-0.75)

Note: IS-ischemic stroke; TIA-transient ischemic attack; Tb-thromboembolism; HS-hemorrhagic stroke; S-stroke; N[a]-incidence per 100 person-years; hazard ratio (rate *10^3) [95% CI]; N (events)[b]-events rate/100 patients-years; Absolute risk% (95% CI); SE-systemic embolism

In regard to safety outcomes across the various studies, treatment-related events such as myocardial infarction, bleeding, and intracranial hemorrhage was observed in both the (patients treated with NOACs and those in comparators (VKA and warfarin). Generally, the NOACs were associated with lower hazard ratios across the adverse events, including mortality, compared to warfarin and VKA (Table 3). Warfarin was associated with high incidences of mortality across a number of studies with increased events of IH and bleeding compared to NOACs (Table 3).

Discussion

This LPB trial compares the safety and efficacy of apixaban, dabigatran, or rivaroxaban against warfarin over an extended follow-up period focusing on patients with NVAF. The impact of NOACs on individuals has not yet been directly compared in any prior research. In a sizable patient cohort with AF, the findings revealed that NOACs had relatively low rates of ICH, IS/SE, all major hemorrhage, and all-cause death as referenced to warfarin. Additionally, a significant percentage of patients in the large cohort was prescribed low doses of NOACs, with

Table 3: Safety outcomes of the NOACs versus the comparators across the included studies.

Study	NOACs				Comparator
	Dabigatran	***Rivaroxaban***	***Apixaban***	***Edoxaban***	
Crocetti E, et al. (2021) [41]	M - 0.52 (68.1) MI - 0.84 (68.4) B - 0.81 (36.9))	M - 0.51 (68.6) MI - 0.74 (59.6) B - 0.67 (30.1)	M - 0.69 (111.1) MI - 0.73 (53.6) B - 0.01 (42.3)	M - 0.75 (114.6) MI - 0.73 (58.6) B - 0.78 (38.8)	Warfarin M - 150.3 (130.4–173.1) MI - 93.0 (77.2–112.0) B - 48.4 (37.6–62.3)
Fanaroff AC, et al. (2022) [42]	M - 1.94 B - 1.76	M - 0.65 B - 0.54	M - 1.02 B - 0.92	M - 1.02 B - 1.40	VKA
Melgaard L, et al. (2021) [40]	B - 0.73 MI	B - 0.73 MI	B - 0.73 MI	B - 0.73 MI	Warfarin B, MI
Chan YH, et al. (2018) [39]	M - 5.05* MI - 0.43* B - 2.01* IH - 0.75*	M - 5.97* MI - 0.42* B - 2.06* IH - 0.79*	M - 7.22* MI -0.52* B - 1.52* IH - 0.7*	_	Warfarin M - 9.09* MI - 0.62* B - 3.0* IH - 1.33*
Lip GY, et al. (2021) [33]	B - 4.36[a] IH - 0.45[a]	B - 6.34[a] IH - 0.66[a]	B - 3.88[a] IH - 0.55[a]	_	Warfarin B - 5.66[a] IH - 0.94[a]
Nielsen PB, et al. (2019) [38]	IH - .35% (4.61% to 10.07%)	IH - 5.07% (2.74% to 7.41%)	_	_	Warfarin IH - 7.85% (4.56% to 11.15%)
Briasoulis et al. (2018)	M - 2.3 (209)[b] MI - 0.7 (68)[b] B - 3 (270)[b]	M - 2.8 (227)[b] MI - 0.8 (68)[b] B - 4.2 (339)[b]	_	_	Warfarin M - 5.6 (2080)[b] MI - 1.1 (398)[b] B - 4.5 (1657)[b]
Kohsaka et al. (2019)	B - 0.92 (0.655 to 1.286) IH - 0.79 (0.658 to 0.946)	B - 0.92 (0.693 to 1.213) IH - 0.81 (0.701 to 0.936)	B - 0.76 (0.579 to 0.987) IH - 0.89 (0.579 to 0.987)	B - 0.83 (0.602 to 1.158) IH - 0.81 (0.789 to 1.076)	Warfarin
Li HJ, et al. (2021) [35]	M – 4.62[a] (3.87-7.02) IH – 1.17[a] (0.82-1.67)	M – 8.22[a] (7.03-9.61) IH – 1.42[a] (0.97-2.07)	_	_	Warfarin M-11.53[a] (10.43-12.74) IH – 1.86[a] (1.45-2.39)

Note: M-mortality; MI-myocardial infarction; B-bleeding; S-stroke {hazard ratio (rate *10^3) [95% CI]}

VKA-vitamin K antagonists; IH-intracranial hemorrhage; N*-crude incidences; Absolute risk% (95% CI)

N[a]-incidence per 100 person-years; N (events)[b]-events rate/100 patients-years;

around 62 percent, 88 percent, and 94 per cent of affected role taking low doses of apixaban, dabigatran, and rivaroxaban, respectively. Normalized dose apixaban showed a decreased risk of IS or SE, all major bleeding, as well as ICH when assessed with warfarin. However, to the other two standard dosages of NOACs.

In comparison to the warfarin group, all 3 of the standard-dose NOACs, apixaban, dabigatran, and rivaroxaban, showed decreased mortality. As a result, the risk of ICH, IS/SE severe haemorrhage, and death were all less than those of warfarin, with three low-dose NOACs performing similarly to those without subgrouping. Many studies have not explicitly compared the effectiveness and safety of these NOACs compared to warfarin in other individuals. Using national datasets from Denmark, a study compared typical dose NOACs with warfarin in anticoagulant-nave individuals with AF [43]. They came to the conclusion that the risk of ischemic stroke was the same for warfarin and all NOACs. However, compared to apixaban and dabigatran, the risk of decease or all-important bleeding was much higher with rivaroxaban and warfarin. Another study compared three NOACs against warfarin in a major US insurance database to explore the efficacy and safety of each medicine. The findings showed that when compared to warfarin, apixaban had reduced risks of severe bleeding and stroke, dabigatran had lower risks of major bleeding but same risks of stroke and rivaroxaban had comparable chances of major bleeding and stroke [41, 42]. Retrospective new-user cohort research was done utilizing the US Medicare system, enrolling 118,891 patients with NVAF. According to their research, standard-dose rivaroxaban was linked to more cases of serious GIB and ICH than typical dose dabigatran. Dabigatran and apixaban, in overall, appeared to have comparable safety profiles and a lesser risk of serious bleeding than rivaroxaban, according to most real-world evidence [44]. It's important to note that each of these key trials had a distinct patient population as its primary emphasis. Previous research showed that patients with AF are more susceptible to warfarin and had a significantly higher chances of ICH than control group, even when the optimal range for all international normalized ratios is between 2 and 3 [40,45, and 46].

Warfarin has thus been administered or utilized insufficiently in nations like Asian individuals with AF. Asian people recompense the price for under dosing or underusing warfarin, as opposed to non-Asians, with a great risk of thromboembolic events [33]. Despite the fact that an INR lowers the therapeutic range of two clearly has less of an antithrombotic impact, it may be safer for Asian patients since it lowers the risk of warfarin-related bleeding. Sadly, despite being under dosed, warfarin patients who are Asian still have a higher risk of major bleeding than patients who are not Asian, which may be due to greater VINRC (variability in international normalized ratio control) [33]. Previous research has also shown that the length of time spent outside of the therapeutic variety can forecast a great bleeding risk in warfarin patients [6]. NOACs demonstrated superior efficiency and safety of individuals than in control, according to a subdivision analysis of critical studies in Asians [33]. When compared to warfarin, apixaban has a significantly lesser risk of serious bleeding as shown (HR, 0.52; 95% CI, 0.34-0.80) and a trend toward fewer thromboembolic events such as (HR, 0.73; 95% CI, 0.49-1.09) in the Asian subgroup analysis of the ARISTOTLE study [47]. Similar findings were found in this trial, namely a markedly decreased risk of IS/SE (HR, 0.55; 95% CI, 0.43-0.69) and all main bleeding (HR, 0.41; 95% CI, 0.31-0.53) when compared

to warfarin. The lower dose of NOAC then was individualistically evaluated with warfarin amongst the three major NOAC articles was dabigatran at 110 mg twice a day [6]. According to the RE-LY trial's Asian subgroup analysis, low-dose dabigatran was associated with a comparable thromboembolic risk occurrence (HR, 0.82; 95% CI, 0.55-1.24) but considerably less risk of serious bleeding as per (HR, 0.57; 95% CI, 0.38-0.86) than warfarin [37, 16]. The results from the RE-LY trial, which involved 88 per cent of patients receiving dabigatran low-dose, are consistent with those from Taiwan, showing decreased risks of thromboembolic events as measured (HR, 0.82; 95% CI, 0.68-0.98) and serious bleeding (HR, 0.65; 95% CI, 0.53-0.80) and for dabigatran compared to warfarin ROCKET-AF trial's subgroup analyses of Asian participants revealed that rivaroxaban and warfarin had comparable risks of thromboembolic events (HR, 0.76, 95% CI, 0.42-1.37) and all main bleeding (HR, 0.63, 95% CI,0.37-1.09,) respectively [17,24,27 and 38]. The usage of low-dose NOACs has been seen as a global trend in recent real-world practice [48]. Doctors frequently take low-dose of NOACs to prevent bleeding because anticoagulation is typically used as a prophylactic treatment in AF patients. In the current Asian population, a high proportion of low-dose NOAC prescriptions was also noted [29,39]. Asian patients tend to have smaller bodies than non-Asians, which makes doctors hesitant to give them standard-dose NOACs because of the iatrogenic risk of bleeding events brought on by oral anticoagulants, the high prevalence of elderly affected role, and the numerous underlying comorbidities and long-lasting kidney illnesses that Asian individuals tend to have. Nevertheless, the propensity to prescribe low-dose of NOACs may result in insufficient efficacy in preventing strokes [3,31 and 37].

According to the ORBIT-AF II registry, the under dosing of NOACs was linked to a higher incidence of cardiovascular hospitalization [48]. Furthermore, recent research found that taking apixaban below the recommended dose without adhering to the dose-drop requirements was linked to a nearly fivefold higher risk of stroke. Curiously, patients who received either dabigatran or rivaroxaban did not have the decreased efficacy linked to low-dose apixaban. The patients who received three low-dose of NOACs in comparison to warfarin, our trial did not indicate a tendency toward an increase in thromboembolic events [49]. It should be noted that the stated risks of IS/SE every year for apixaban, rivaroxaban, and dabigatran, in this analysis were 2.26 per cent, 2.74 per cent, and 2.84 per cent, correspondingly, which was similar to the prime efficacy results of the NOACs trials. The clinical practice raises significant questions about the efficacy and safety of specific NOACs. A study showed in meta-analysis dabigatran, edoxaban, and apixaban, though not rivaroxaban were the key NOACs that lowered the risk of severe bleeding and ICH in patients with AF and VHD [50]. Despite the fact that the risk of ICH was similar to that of warfarin, significant bleeding became more common in patients with VHD receiving rivaroxaban. The data from the study also showed variations in the efficacy of various NOACs. Dabigatran was primarily responsible for the reduction in the risk of VTE. However, individuals taking both dabigatran and rivaroxaban also had a reduction in the risk of ICH and mortality.

Limitations of the Study

The study only acknowledged English-published studies that contained a lot of information that was relevant to this article. Although it is impossible to draw a reliable generalized conclusion about the effectiveness and the safety of NOACs over warfarin in valvular and nonvalvular due to the small and continuously variable number of subjects included in each individual included study. The results must be understood in light of the observational aspect of the study, as well as the fact that the data used was gathered for administrative purposes. Confounding that is unmeasured or residual is likely to continue and could contribute to some of the observed relationships. Additionally, due to the size of the study population, it was not possible to explore new treatment methods that had emerged since the applied study period, such as the use of statins and blood pressure control. Because of a lack of imaging data, it could not determine the hematoma's size and position. Therefore, it is impossible to completely ignore the impact of any underlying cerebral small artery illnesses that may have contributed to the bleeding itself and may do so in the future. Lobar bleeding has been proven to be much more predictive of bleeding recurrence than non-labor haemorrhage. According to the falsification endpoint analysis, confounding does not appear to be the main factor contributing to the outcomes. The choice of treatment plan and agent may have been influenced by indication bias, which may also be present. Nevertheless, the dispersals of the proclivity to receive either a NOAC or the warfarin were strikingly similar, showing that the modeling approach adequately eliminated baseline confounding to enable the inference of causality from the observed relationships. A NOAC agent seems preferred to warfarin amongst those individuals for whom OAC therapy has been determined to be appropriate.

Conclusion

The information demonstrated that NOAC was just as efficacious as warfarin in preventing ischemic stroke and that its risk of bleeding in people with AF and VHD was comparable. In addition, NOAC decreased risks for VTE, ICH, and death than warfarin. Further study is required to confirm the efficacy and safety of NOACs in this subgroup due to the small number of patients with severe VHD in the current study. The aim of this review was to further knowledge of the safety and effectiveness of NOACs in individuals with VHD and AF. Rivaroxaban and dabigatran were linked to relatively low risks of death and non-gastrointestinal bleeding in individuals without prosthetic valves, as well as rates of stroke that were comparable to warfarin. As a result, for patients with no hemodynamically substantial valvular disease necessitating surgery, doctors have less than one anticoagulant alternative available. Additional testing of the findings is necessary, particularly in patients with VHD and high thromboembolic risk conditions, including mitral stenosis and rheumatic valvular illness.

References

1. Inoue H, Fujiki A, Origasa H, Ogawa S, Okumura K, et al. (2009) Prevalence of atrial fibrillation in the general population of Japan: an analysis based on periodic health examination. Int J Cardiol 137: 102-107.

2. JCS Joint Working Group (2014) Guidelines for pharmacotherapy of atrial fibrillation (JCS 2013). Circ J 78: 1997-2021. https://doi.org/10.1253/circj.CJ-66-0092

3. Wolf PA, Abbott RD, Kannel WB (1991) Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke 22: 983-988. https://doi.org/10.1161/01.str.22.8.983

4. Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, et al. (2006) ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 114: e257-354. https://doi.org/10.1093/eurheartj/ehl176

5. Steffel J, Collins R, Antz M, Cornu P, Desteghe L, et al. (2021) 2021 European Heart Rhythm Association practical guide on the use of non-vitamin k antagonist oral anticoagulants in patients with atrial fibrillation. Europace 23: 1612-1676. https://doi.org/10.1093/europace/euab065

6. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, et al. (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361: 1139-1151. https://doi.org/10.1056/NEJMoa0905561

7. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, et al. (2013) Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 369: 2093-2104. https://doi.org/10.1056/NEJMoa1310907

8. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, et al. (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365: 981-992. https://doi.org/10.1056/NEJMoa1107039

9. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, et al. (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365: 883-891. https://doi.org/10.1056/NEJMoa1009638

10. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, et al. (2014) Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 383: 955-962. https://doi.org/10.1016/S0140-6736(13)62343-0

11. Li X, Deitelzweig S, Keshishian A, Hamilton M, Horblyuk R, et al. (2017) Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in 'real-world' clinical practice. A propensity-matched analysis of 76,940 patients. Thromb Haemost 117: 1072-1082. https://doi.org/10.1160/TH17-01-0068

12. Lip GYH, Keshishian A, Kamble S, Pan X, Mardekian J, et al. (2016) Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. A propensity score matched analysis. Thromb Haemost 116: 975-986. https://doi.org/10.1160/TH16-05-0403

13. Russo-Alvarez G, Martinez KA, Valente M, Bena J, Hu B, et al. (2018) Thromboembolic and major bleeding events with rivaroxaban versus warfarin use in a real-world setting. Ann Pharmacother 52: 19-25. https://doi.org/10.1177/1060028017727290

14. Coleman CI, Briere JB, Fauchier L, Levy P, Bowrin K, et al. (2019) Meta-analysis of real-world evidence comparing non-vitamin K antagonist oral anticoagulants with vitamin K antagonists for the treatment of patients with non-valvular atrial fibrillation. J Mark Access Health Policy 7: 1574541. https://doi.org/10.1080/20016689.2019.1574541

15. Kohsaka S, Katada J, Saito K, Terayama Y (2018) Safety and effectiveness of apixaban in comparison to warfarin in patients with nonvalvular atrial fibrillation: a propensity-matched analysis from Japanese administrative claims data. Curr Med Res Opin 34: 1627-1634. https://doi.org/10.1080/03007995.2018.1478282

16. Kohsaka S, Murata T, Izumi N, Katada J, Wang F, et al. (2017) Bleeding risk of apixaban, dabigatran, and low-dose rivaroxaban compared with warfarin in Japanese patients with non-valvular atrial fibrillation: a propensity matched analysis of administrative claims data. Curr Med Res Opin 33: 1955-1963. https://doi.org/10.1080/03007995.2017.1374935

17. Inoue H, Umeyama M, Yamada T, Hashimoto H, Komoto A, et al. (2019) Safety and effectiveness of apixaban in Japanese patients with nonvalvular atrial fibrillation in clinical practice: A regulatory postmarketing surveillance, the STANDARD study. J Arrhythm 35: 506-514. https://doi.org/10.1002/joa3.12184

18. Ikeda T, Ogawa S, Kitazono T, Nakagawara J, Minematsu K, et al. (2019) Outcomes associated with under-dosing of rivaroxaban for management of non-valvular atrial fibrillation in real-world Japanese clinical settings. J Thromb Thrombolysis 48: 653-660. https://doi.org/10.1007/s11239-019-01934-6

19. Camm AJ, Fox KAA (2018) Strengths and weaknesses of 'real-world' studies involving non-vitamin K antagonist oral anticoagulants. Open Heart 5: e000788. http://dx.doi.org/10.1136/openhrt-2018-000788

20. Lip GYH (2019) The safety of NOACs in atrial fibrillation patient subgroups: A narrative review. Int J Clin Pract 73: e13285. https://doi.org/10.1111/ijcp.13285

21. List of Approved Products | Pharmaceuticals and Medical Devices Agency.

22. Friberg L, Rosenqvist M, Lip GYH (2012) Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study. Circulation 125: 2298-2307. https://doi.org/10.1161/CIRCULATIONAHA.111.055079

23. Lip GY, Laroche C, Dan GA, Santini M, Kalarus Z, et al. (2014) A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. Europace 16: 308-319. https://doi.org/10.1093/europace/eut373

24. Petty GW, Khandheria BK, Whisnant JP, Sicks JD, O'Fallon WM, et al. (2000) Predictors of cerebrovascular events and death among patients with valvular heart disease: A population-based study. Stroke 31: 2628-2635. https://doi.org/10.1161/01.STR.31.11.2628

25. Avezum A, Lopes RD, Schulte PJ, Lanas F, Gersh BJ, et al. (2015) Apixaban in comparison with warfarin in patients with atrial fibrillation and valvular heart disease: findings from the apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial. Circulation 132: 624-632. https://doi.org/10.1161/CIRCULATIONAHA.114.014807

26. Breithardt G, Baumgartner H, Berkowitz SD, Hellkamp AS, Piccini JP, et al. (2014) Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial. Eur Heart J 35: 3377-3385. https://doi.org/10.1093/eurheartj/ehu305

27. Ezekowitz MD, Nagarakanti R, Noack H, Brueckmann M, Litherland C, et al. (2016) Comparison of dabigatran and warfarin in patients with atrial fibrillation and valvular heart disease: The RE-LY trial (randomized evaluation of long-term anticoagulant therapy). Circulation 134: 589-598. https://doi.org/10.1161/CIRCULATIONAHA.115.020950

28. Li G, Lip GY, Holbrook A, Chang Y, Larsen TB, et al. (2019) Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies. Eur J Epidemiol 34: 173-190. https://doi.org/10.1007/s10654-018-0415-7

29. Hohmann C, Hohnloser SH, Jacob J, Walker J, Baldus S, et al. (2019) Non-vitamin K oral anticoagulants in comparison to phenprocoumon in geriatric and non-geriatric patients with non-valvular atrial fibrillation. Thromb Haemost 119: 971-980. https://doi.org/10.1055/s-0039-1683422

30. Hohnloser SH, Basic E, Nabauer M (2019) Changes in oral anticoagulation therapy over one year in 51,000 atrial fibrillation patients at risk for stroke: a practice-derived study. Thromb Haemost 119: 882-893. https://doi.org/10.1055/s-0039-1683428

31. Chao TF, Liu CJ, Liao JN, Wang KL, Lin YJ, et al. (2016) Use of oral anticoagulants for stroke prevention in patients with atrial fibrillation who have a history of intracranial hemorrhage. Circulation 133: 1540-1547. https://doi.org/10.1161/CIRCULATIONAHA.115.019794

32. Newman TV, Chen N, He M, Saba S, Hernandez I (2020) Effectiveness and safety of restarting oral anticoagulation in patients with atrial fibrillation after an intracranial hemorrhage: analysis of medicare part d claims data from 2010-2016. Am J Cardiovasc Drugs 20: 471-479. https://doi.org/10.1007/s40256-019-00388-8

33. Lip GY, Keshishian AV, Zhang Y, Kang A, Dhamane AD, et al. (2021) Oral anticoagulants for nonvalvular atrial fibrillation in patients with high risk of gastrointestinal bleeding. JAMA Network Open 4: e2120064. https://doi.org/10.1001/jamanetworkopen.2021.20064

34. Moher D, Liberati A, Tetzlaff J, Altman DG, Group TP (2009) Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. Ann Int Med 6: e1000097. https://doi.org/10.7326/0003-4819-151-4-200908180-00135

35. Li HJ, Lin SY, Lin FJ, Hung CS, Wang CC (2021) Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in Asian patients with atrial fibrillation and valvular heart disease. Curr Med Res Opin 37: 535-542. https://doi.org/10.1080/03007995.2021.1885365

36. Kohsaka S, Katada J, Saito K, Jenkins A, Li B, et al. (2020) Safety and effectiveness of non-vitamin K oral anticoagulants versus warfarin in real-world patients with non-valvular atrial fibrillation: a retrospective analysis of contemporary Japanese administrative claims data. Open Heart 7: e001232. http://dx.doi.org/10.1136/openhrt-2019-001232

37. Briasoulis A, Inampudi C, Akintoye E, Alvarez P, Panaich S, et al. (2018) Safety and efficacy of novel oral anticoagulants versus warfarin in medicare beneficiaries with atrial fibrillation and valvular heart disease. J Am Heart Assoc 7: e008773. https://doi.org/10.1161/JAHA.118.008773

38. Nielsen PB, Skjøth F, Søgaard M, Kjældgaard JN, Lip GY, et al. (2019) Non–vitamin K antagonist oral anticoagulants versus warfarin in atrial fibrillation patients with intracerebral hemorrhage. Stroke 50: 939-946. https://doi.org/10.1161/STROKEAHA.118.023797

39. Chan YH, See LC, Tu HT, Yeh YH, Chang SH, et al. (2018) Efficacy and safety of apixaban, dabigatran, rivaroxaban, and warfarin in asians with nonvalvular atrial fibrillation. J Am Heart Assoc 7: e008150. https://doi.org/10.1161/JAHA.117.008150

40. Melgaard L, Overvad TF, Jensen M, Christensen TD, Lip GY, et al. (2021) Effectiveness and safety of NOAC versus warfarin in patients with atrial fibrillation and aortic stenosis. J Am Heart Assoc 10: e022628. https://doi.org/10.1161/JAHA.121.022628

41. Crocetti E, Cattaneo S, Bergamaschi W, De Servi S, Russo AG (2021) Effectiveness and safety of non-vitamin K oral anticoagulants in non-valvular atrial fibrillation

patients: results of a real-world study in a metropolitan area of Northern Italy. J Clin Med 10: 4536. https://doi.org/10.3390/jcm10194536

42. Fanaroff AC, Vora AN, Lopes RD (2022) Non-vitamin K antagonist oral anticoagulants in patients with valvular heart disease. Eur Heart J Suppl 24: A19-A31. https://doi.org/10.1093/eurheartj/suab151

43. Lip GY, Keshishian A, Kang A, Luo X, Atreja N, et al. (2022) Effectiveness and safety of oral anticoagulants in non-valvular atrial fibrillation patients with prior bleeding events: a retrospective analysis of administrative claims databases. J Thromb Thrombolysis 54: 33-46. https://doi.org/10.1007/s11239-022-02660-2

44. Graham DJ, Reichman ME, Wernecke M, Hsueh YH, Izem R, et al. (2016) Stroke, bleeding, and mortality risks in elderly medicare beneficiaries treated with dabigatran or rivaroxaban for nonvalvular atrial fibrillation. JAMA Intern Med 176: 1662-1671. https://doi.org/10.1001/jamainternmed.2016.5954

45. van Asch CJ, Luitse MJ, Rinkel GJ, van der Tweel I, Algra A, et al. (2010) Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis. Lancet Neurol 9: 167-176. https://doi.org/10.1016/S1474-4422(09)70340-0

46. Dang MT, Hambleton J, Kayser SR (2005) The influence of ethnicity on warfarin dosage requirement. Ann Pharmacother 39: 1008-1012. https://doi.org/10.1345/aph.1E566

47. Goto S, Zhu J, Liu L, Oh BH, Wojdyla DM, et al. (2014) Efficacy and safety of apixaban compared with warfarin for stroke prevention in patients with atrial fibrillation from East Asia: a subanalysis of the apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial. Am Heart J 168: 303-309. https://doi.org/10.1016/j.ahj.2014.06.005

48. Steinberg BA, Shrader P, Thomas L, Ansell J, Fonarow GC, et al. (2016) Off-label dosing of non-vitamin K antagonist oral anticoagulants and adverse outcomes: The ORBIT-AF II registry. J Am Coll Cardiol 68: 2597-2604. https://doi.org/10.1016/j.jacc.2016.09.966

49. Yao X, Shah ND, Sangaralingham LR, Gersh BJ, Noseworthy PA (2017) Non-vitamin K antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction. J Am Coll Cardiol 69: 2779-2790. https://doi.org/10.1016/j.jacc.2017.03.600

50. Pan KL, Singer DE, Ovbiagele B, Wu YL, Ahmed MA, et al. (2017) Effects of non-vitamin K antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and valvular heart disease: a systematic review and meta-analysis. J Am Heart Assoc 6: e005835. https://doi.org/10.1161/jaha.117.005835